Trial · NCT00051558
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD) | 18 month endpoint | The intention-to-treat analysis was performed using all randomized and treated patients. | grams per square centimeters | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD), Female Subset | 18 month endpoint | The intention-to-treat analysis was performed using all randomized and treated patients (female only subset). | grams per square centimeters | LEAST_SQUARES_MEAN |
| SECONDARY | Time Course of Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Women and Men Combined | 3, 6, 12, 18, 24, 36 months | The intention-to-treat analysis was performed using all randomized and treated patients. No missing data were imputed. | grams per square centimeters | LEAST_SQUARES_MEAN |
| SECONDARY | Time Course of Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Female Subset | 3, 6, 12, and 18 months | The intention-to-treat analysis was performed using all randomized and treated patients. No missing data were imputed. | grams per square centimeters | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Women and Men Combined | 24 and 36 months and Endpoint at 36 months | The intention-to-treat analysis was performed using all randomized and treated patients. For 24 and 36 month time points, no missing data were imputed. However, at the 36 month endpoint, last observation carried forward analysis was applied. | grams per square centimeters | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Femoral Neck Bone Mineral Density (BMD), Women and Men Combined | 18, 24, 36 months, and 18 and 36 month endpoints | The intention-to-treat analysis was performed using all randomized and treated patients. For 18, 24 and 36 month time points, no missing data were imputed. However at the 36 month endpoint, last observation carried forward analysis was applied. | grams per square centimeters | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Total Hip Bone Mineral Density (BMD), Women and Men Combined | 18, 24, 36 months, and 18 and 36 month endpoints | The intention-to-treat analysis was performed using all randomized and treated patients. For 18, 24 and 36 month time points, no missing data were imputed. However, at 18 and 36 month endpoints, last observation carried forward analyses were applied. | grams per square centimeters | LEAST_SQUARES_MEAN |
| SECONDARY | Time Course of Change From Baseline in Femoral Neck Bone Mineral Density (BMD), Women and Men Combined | 12, 18, 24, and 36 months | The intention-to-treat analysis was performed using all randomized and treated patients. No missing data were imputed. | grams per square centimeters | LEAST_SQUARES_MEAN |
| SECONDARY | Time Course of Change From Baseline in Total Hip Bone Mineral Density (BMD), Women and Men Combined | 12, 18, 24, and 36 months | The intention-to-treat analysis was performed using all randomized and treated patients. No missing data was imputed. | grams per square centimeters | LEAST_SQUARES_MEAN |
| SECONDARY | Time Course of Change From Baseline in Bone Turnover Markers in Subset of Patients - Serum N-terminal Propeptide of Type 1 Procollagen | 1, 6, 18, and 36 months | Subset of patients with measures of biochemical markers | percent | MEAN |
| SECONDARY | Time Course of Change From Baseline in Bone Turnover Markers in Subset of Patients - Serum C-terminal Propeptide of Type 1 Procollagen | 1, 6, 18, and 36 months | Subset of patients with measures of biochemical markers. | percent | MEAN |
| SECONDARY | Time Course of Change From Baseline in Bone Turnover Markers in Subset of Patients - Bone-Specific Alkaline Phosphatase | 1, 6, 18, and 36 months | Subset of patients with measures of biochemical markers | percent | MEAN |
| SECONDARY | Time Course of Change From Baseline in Bone Turnover Markers in Subset of Patients - Serum Type 1 Collagen Degradation Fragments | 1, 6, 18, and 36 months | Subset of patients with measures of biochemical markers | percent | MEAN |
| SECONDARY | Time Course of Change From Baseline in Bone Turnover Markers in Subset of Patients - Osteocalcin | 1, 6, 18, and 36 months | Subset of patients with measures of biochemical markers | percent | MEAN |
| SECONDARY | Any Fracture, Nonvertebral Fractures, Vertebral Fractures, Clinical Vertebral Fractures, and Severity Fractures | 36 months | For vertebral fractures, only those patients with baseline and postbaseline spinal radiographs were included in the analysis. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00051558/outcomes